Although loss of CXCR4 results in neutrophil egress from the bone marrow, CXCR4 acquisition is relevant for neutrophil infiltration into the tumor; therefore, inhibiting the CXCL12/CXCR4 axis could also result in therapeutic effects (Xue et al., 2017). The gene discussed is CXCR4; the disease is neoplasm.